Home News DGAP-News: curasan AG launches synthetic bone substitute material Osbone (R) on the...

DGAP-News: curasan AG launches synthetic bone substitute material Osbone (R) on the market


Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG. For the content of Communication is the issuer / publisher responsible.
General Standard of Deutsche Börse AG noted curasan AG (ISIN: DE 000 549 453 8) launches this week, the marketing of the synthetic non-resorbable bone substitute material Osbone (R).
The company now offers users a product for Such applications, which from the outset a high stability of the Body of the filled bone defect claim.
Osbone (R) is aimed at the target group of the implant, oral and Pine,
Facial surgeons and surgical dentists working It will be initially marketed in-house of curasan AG.
Hans Dieter Rössler, CEO of curasan AG explains:?, at this stage there are no suitable Partner has licensed the marketing rights in Europe Dental market. Some potential candidates are serious Considerations, it’s the segment of bone regeneration in their portfolio enter new or strengthen it. These companies are aware, however, that they must position themselves differently than in the past to this Area to be successful. The associated decision-making and Implementation process will take us too long. We have therefore developed a strategy that centrally controlled demand creation through a virtual marketing and To initiate a marketing concept in the dental market without its own Field service organization to build. The distribution comes with a local dealer network each region will be covered. "
As an alternative to synthetic materials of animal origin carries the ceramic material Osbone (R), any residual risks in terms Allergies or the transmission of infectious diseases and is tissue-awarded.
With Osbone (R), the doctor’s patients, a proven Material without biological background to offer. This allows him a simplified patient education, because it reduces Osbone (R), its Effort and often underestimated risk of liability to a superficial explanation.
About curasan AG: The listed curasan AG (ISIN: DE 000 549 453 8) is a leading Companies in the field of bone and tissue regeneration. In addition to the synthetic bone material Cerasorb (R), the Company has a future product pipeline built. Objective in the coming years is to to bring more medical devices to market and have well to distribute positioned contractors in various market segments. www.curasan.de
Andrea Weidner, curasan AG Tel +49 (0) 6027 40 900-51 Fax +49 (0) 6027 40 900-39 andrea.weidner @ curasan.de www.curasan.de
fr financial relations gmbh Jörn Gleisner Tel +49 (0) 69 95 90 83 20 Fax +49 (0) 69 95 90 83 99 j.gleisner @ financial-relations.de
15.03.2010 14:21 Ad-hoc news, financial news and Press releases transmitted by DGAP. Media archive at http://www.dgap-medientreff.de and http://www.dgap.de
Language: German Company: curasan AG
Lindigstrasse 4
63801 Kleinostheim
Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549,453 Exchanges: Regulated Market in Frankfurt (General Standard);
Unofficial Market in Berlin, Munich, Dusseldorf, Stuttgart,
End of News DGAP News-Service